Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1992 1
1993 2
1994 3
1995 3
1996 3
1997 3
1998 2
1999 3
2000 6
2001 5
2002 3
2003 9
2004 8
2005 6
2006 3
2007 8
2008 5
2009 3
2010 8
2011 6
2012 6
2013 10
2014 8
2015 6
2016 16
2017 7
2018 10
2019 10
2020 16
2021 18
2022 20
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

219 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study.
Bujko K, Wyrwicz L, Rutkowski A, Malinowska M, Pietrzak L, Kryński J, Michalski W, Olędzki J, Kuśnierz J, Zając L, Bednarczyk M, Szczepkowski M, Tarnowski W, Kosakowska E, Zwoliński J, Winiarek M, Wiśniowska K, Partycki M, Bęczkowska K, Polkowski W, Styliński R, Wierzbicki R, Bury P, Jankiewicz M, Paprota K, Lewicka M, Ciseł B, Skórzewska M, Mielko J, Bębenek M, Maciejczyk A, Kapturkiewicz B, Dybko A, Hajac Ł, Wojnar A, Leśniak T, Zygulska J, Jantner D, Chudyba E, Zegarski W, Las-Jankowska M, Jankowski M, Kołodziejski L, Radkowski A, Żelazowska-Omiotek U, Czeremszyńska B, Kępka L, Kolb-Sielecki J, Toczko Z, Fedorowicz Z, Dziki A, Danek A, Nawrocki G, Sopyło R, Markiewicz W, Kędzierawski P, Wydmański J; Polish Colorectal Study Group. Bujko K, et al. Ann Oncol. 2016 May;27(5):834-42. doi: 10.1093/annonc/mdw062. Epub 2016 Feb 15. Ann Oncol. 2016. PMID: 26884592 Free article. Clinical Trial.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
An Overlooked Hepcidin-Cadmium Connection.
Płonka D, Wiśniewska MD, Peris-Díaz MD, Krężel A, Bonna AM, Bal W. Płonka D, et al. Among authors: bal w. Int J Mol Sci. 2022 Dec 7;23(24):15483. doi: 10.3390/ijms232415483. Int J Mol Sci. 2022. PMID: 36555126 Free PMC article.
Structures of Silver Fingers and a Pathway to Their Genotoxicity.
Kluska K, Veronesi G, Deniaud A, Hajdu B, Gyurcsik B, Bal W, Krężel A. Kluska K, et al. Among authors: bal w. Angew Chem Int Ed Engl. 2022 Mar 14;61(12):e202116621. doi: 10.1002/anie.202116621. Epub 2022 Feb 3. Angew Chem Int Ed Engl. 2022. PMID: 35041243 Free PMC article.
Development of a centralised triage centre for children with cancer and blood disorders in response to the humanitarian crisis in Ukraine.
Salek M, Mueller A, Alanbousi I, Cepowska Z, Dutkiewicz M, Earl J, Evseev D, Kizyma R, Kliuchkivska K, Kolodrubiec J, Matczak K, Nogovitsyna Y, Oszer A, Pogorelyy M, Raciborska A, Rasul S, Sokolowski I, Sopilnyak A, Vinitsky A, Wlodarski MW, Wobst N, Yakimkova T, Rodriguez-Galindo C, Wise PH, Mlynarski W, Agulnik A; SAFER Ukraine Collaborative. Salek M, et al. Lancet Oncol. 2023 Dec;24(12):1315-1318. doi: 10.1016/S1470-2045(23)00456-4. Lancet Oncol. 2023. PMID: 38039989 No abstract available.
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment.
Cybulska-Stopa B, Piejko K, Ostaszewski K, Dziura R, Galus Ł, Ziółkowska B, Kempa-Kamińska N, Ziętek M, Bal W, Kamycka A, Dudzisz-Śledź M, Kubiatowski T, Kamińska-Winciorek G, Suwiński R, Mackiewicz J, Czarnecka AM, Rutkowski P. Cybulska-Stopa B, et al. Among authors: bal w. Melanoma Res. 2023 Jun 1;33(3):208-217. doi: 10.1097/CMR.0000000000000885. Epub 2023 Apr 3. Melanoma Res. 2023. PMID: 37015054
219 results